Fraunhofer ITEM: News

Press release / 16.4.2024

Miniature Lab

New opportunity for cancer therapy: Miniature Lab provides insights into metastases development.

News / 21.11.2023

Rapid therapies against viral diseases

As a finalist in the third round of the SPRIND Challenge, iGUARD receives follow-up funding of 2.5 million euros. 


Project / 19.9.2023

Environmental risk assessment (ERA)

Why does the environmental risk assessment for drugs need to be updated? 



3 million euros allocated for research into the development of innovative technologies for brain regeneration.

Press release / 3.7.2024

DNA, RNA and peptides as storage media

BIOSYNTH – “Modular high-throughput micro-platform for mass data storage of the future from synthetic biology”


News / 26.1.2024

Research on alternatives to animal studies on behalf of European Chemicals Agency (ECHA)

Scientific studies on the reliability and relevance of new approach methodologies (NAMs) as alternatives to animal studies.


Highlight / 18.9.2023

Toxicological risk assessment for PFAS

What amount of PFAS is it safe to ingest? At Fraunhofer ITEM, we are investigating how PFAS impact people’s health. 

News / 12.1.2024

Reinforcing core competencies

Succession to Professor Thomas Thum to act as institute director of Fraunhofer ITEM and take up new role as chair of Toxicology at MHH.

Our research and development expertise

For more than four decades, we have been developing solutions for human health


Lung research

Research for healthy lungs: Airway research has been a focus at Fraunhofer ITEM ever since the institute was founded. 

Medical and pharmaceutical engineering

Next to innovative inhalation technologies, our focus is on developing novel technologies for administration of therapeutic aerosols by means of smart drug/device combination products.


Malignant disease research

The Fraunhofer ITEM Division of Personalized Tumor Therapy in Regensburg is aimed at understanding a patient’s individual condition, establishing appropriate diagnostics and optimizing therapies.

Bioinformatics and AI

Our researchers develop methods for preparation, analysis and visualization of biomedical data, as well as data models and data analysis pipelines. The focus is on the mapping of cellular and regulatory processes and their translation into applications.


RNA technologies

RNA-based therapeutics are a drug class with huge potential for medicine. Fraunhofer ITEM researchers develop novel drugs and methods for RNA-based therapeutic concepts.



Based on the next generation risk assessment concept, Fraunhofer ITEM develops new assessment strategies to provide predictive models for assessing the safety of compounds, active pharmaceutical ingredients and drugs.


Immunology and infection research

The development, formulation and mode of delivery of anti-infective agents, for example for inhaled administration as drug aerosols, are research topics of current interest at the institute.

Our services


Chemical Safety and Assessment


Translational Biomedical Engineering


Personalized Tumor Therapy

From molecular analysis to personalized therapy:


Meet Fraunhofer ITEM at fairs and congresses



Fraunhofer CIMD Winter School 2024

The Winter School will take place again this year. As every year, the 4-day school is all about our 4Ds (Drugs, Diagnostics, Data and Devices). Each day focuses on a different "D".
more info


Advanced RNA Methods & Applications

Deep dive into RNA advanced methods and applications - in the two-day training course at Fraunhofer ITEM in Hannover | October 01-02, 2024! Read more here.
more info


Fraunhofer CIMD Symposium RNA-Based Therapeutics

RNA-research in the focus - at the Fraunhofer CIMD Symposium RNA-Based Therapeutics at Fraunhofer ITEM in Hannover on September 30, 2024. Read more here.
more info


Models of Lung Disease 2024

June 20 and 21 - our conference "Models of Lung Disease" for experts in lung research. Join us! We would be pleased to welcoming you there.
more info

About Fraunhofer ITEM

The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is one of 76 institutes and research institutions of the Fraunhofer-Gesellschaft, the world’s leading applied research organization. Protecting man from health hazards in our industrialized world and contributing to the development of novel therapeutic approaches are the aims Fraunhofer ITEM is pursuing with its contract research. With a focus on lung research, our R&D portfolio includes three business areas: Drug Development, Chemical Safety and Translational Biomedical Engineering. In addition, our scientists in Regensburg do research in the field of personalized tumor therapy.

With a staff of around 450 at its locations in Hannover, Braunschweig and Regensburg, the institute cooperates with industry, service providers, and public authorities in projects that drive economic development and serve the wider benefit of society.


More information about Fraunhofer ITEM